AI주식인사이트AI Stock Insight
C

박셀바이오

323990KOSDAQ

45.0 / 100

Reference Date: 2026-10-23

Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 4.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Parkcell Bio is a biotech company specializing in cancer immunotherapy, developing various platforms such as Vax-NK and Vax-CAR for immune cell therapies and targeted anticancer drugs. It also expands its pet healthcare business through its veterinary immunomodulatory drug 'Vaxleukin-15' and has enhanced its commercialization capabilities by constructing an advanced manufacturing platform following the completion of its new headquarters in 2025.

Number of Employees

91people

Average Salary

49.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.58Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
-20.04Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
3.69Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲7004.4% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼16.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -17.7% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 4,140Won52-week high 11,00052-week low 3,585
1-month return2.0Point

1m -4.50% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0